Navigation Links
Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
Date:11/7/2007

SAN DIEGO, CA, Nov. 7 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation (TSX: NVN) announced today financial results for the third quarter ended September 30, 2007. All amounts, unless specified otherwise, are in Canadian dollars.

Nventa reported a net loss of $3.1 million or $0.01 per share, for the three months ended September 30, 2007, compared to a net loss of $2.3 million, or $0.03 per share, for the same period in 2006. For the nine months ended September 30, 2007, the Company reported a net loss of $10.1 million, or $0.05 per share, compared to a net loss of $8.0 million, or $0.10 per share, for the same period in 2006. The Company's net loss for the nine months ended September 30, 2007 included approximately $0.8 million in one-time corporate restructuring expenses.

The Company had cash and cash equivalents of $14.3 million as of September 30, 2007.

RECENT NVENTA HIGHLIGHTS

- Initiated and dosed the first cohort of patients in the Company's

HspE7 Phase 1 clinical trial in cervical intraepithelial neoplasia;

- Raised $8.6 million in additional capital through a Short Form

Prospectus Offering;

- Strengthened management team with addition of David Duncan Jr.,

Vice President of Finance;

- Assembled distinguished group of international experts for Clinical

and Scientific Advisory Board;

- Presented additional data at the 24th International Papillomavirus

Conference and Clinical Workshop that demonstrate that new HspE7

promotes more potent immune responses;

- Granted new U.S. patent for Nventa's CoVal(TM) fusions covering their

use in patients with human papillomavirus (HPV)-related diseases;

- Published data in Clinical and Vaccine Immunology demonstrating

ability of new HspE7 to elicit long-lasting tumor protection in vivo,

suggesting that HspE7 may have utility in (HPV)-infected
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
9. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
10. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
11. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015  AmnioChor Inc., an early stage biotech ... pleased to announce that the Musculoskeletal Transplant Foundation of ... invest in their seed round of development of the ... capabilities. AmnioChor,s technology allows cryopreservation of ... stem cells living within those tissues. Amnion is a ...
(Date:7/29/2015)... , July 29, 2015  Pfenex Inc. (NYSE MKT: ... results will be released on Thursday, August 13, 2015, ... Time, Pfenex management will host a conference call to ... A press release outlining the financial results and business ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) ...
(Date:7/29/2015)... Madison, NJ (PRWEB) , ... July 29, 2015 , ... ... and approval of combination products , in particular, drug/device combinations. The current system ... innovation by the Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson ...
(Date:7/29/2015)... 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... selected an optimized Erk inhibitor molecule for development, ... of a new class of potential cancer therapies. ... prime target for therapeutic intervention in cancer. Recently ... benefits for B-Raf and Mek inhibitors. Erk inhibitors ...
Breaking Biology Technology:The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... YORK, Jan. 15 - The Michael J. Fox,Foundation ... total funding for seven research studies aiming to ... drug makers, to,therapeutically target two genes -- LRRK2 ... only partially understood, role in Parkinson,s disease., ...
... Kan., Jan. 15 The Kansas Bioscience,Authority ... bring together,researchers nationwide to create products that ... diseases to disrupt the national economy or,to ... new Collaborative Biosecurity Research Initiative,(CBRI) are to ...
... Group plc (AIM:,PRG), the international pharmaceutical services ... Senior Director, Clinical Trial Management,specializing in oncology-related ... a leading role in the operations, strategic ... portfolio of oncology,business., Over the past ...
Cached Biology Technology:The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinson's Disease 2Collaborative Biosecurity Research Initiative Launched to Target Animal and Public Health Threats Nationally 2Collaborative Biosecurity Research Initiative Launched to Target Animal and Public Health Threats Nationally 3Premier Research Names Patrick Melvin as Senior Director, Clinical Trial Management 2
(Date:7/9/2015)... , July 9, 2015  Unchained Labs just ... its acquisition of Avid Nano. Avid Nano designs, ... (DLS) systems.    Also today, Unchained ... and easiest to use protein sizing system. The ... a protein,s hydrodynamic size, size distribution, aggregation population ...
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
(Date:7/7/2015)... , July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... the growing mobile commerce market announces a revised version of one ... The commercial will air on CNBC in New York ... and San Francisco metro areas. ... focuses on Wocket,s ability to replace all the cards in your ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... FL. Research to be presented at the upcoming ... Ingestive Behavior (SSIB), the foremost society for research into ... people can become dependent on highly palatable foods and ... the behaviors we observe in drug addicts and those ...
... can make a significant contribution to carbon storage and, ecologists ... and gardeners planted and maintained more trees. The study, published ... Applied Ecology , is the first to quantify how much ... Europe. Using satellite data and information gathered by visiting ...
... Toronto, ON - When it comes to how they ... from humans. Recent studies showed that even genetically ... a disease. This is because each twin has distinct personal ... the same is likely true for forest trees as well, ...
Cached Biology News:Evidence for 'food addiction' in humans 2Plants in cities are an underestimated carbon store 2New research shows forest trees remember their roots 2
... bromide), 50mg/vial. MTT is a pale yellow ... to yield a dark blue formazan product. ... freshly dead cells do not cleave significant ... component of Chemicons MTT assay kit, Catalog ...
Mouse polyclonal antibody to ALS2CR8 - amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 8...
Determin interaction of your protein with Echelons lipids...
Anti-Human Complement Component C4c, IgY fraction (Polyclonal) (chicken IgY)...
Biology Products: